Sub menu

 

 

Celltrion Healthcare Australia Pty Ltd.

Regulatory activities for this sponsor.

Type

Date

4 result(s) found, displaying 1 to 4

  • Osenvelt, Stoboclo

    Australian public assessment report (AusPar)
    Osenvelt has been approved for the prevention of skeletal related events in patients with multiple myeloma and in patients with bone metastases from solid tumours. Stoboclo has been approved for the treatment of osteoporosis in postmenopausal women. Stoboclo significantly reduces the risk of vertebral, non-vertebral and hip fractures.

  • AVTOZMA

    Australian public assessment report (AusPar)
    AVTOZMA (tocilizumab), a biosimilar to ACTEMRA, has been approved to treat multiple autoimmune and inflammatory conditions.

  • Vegzelma

    Prescription medicine decision summary
    Vegzelma (bevacizumab) is approved to treat cancer.

  • Regkirona

    Prescription medicine decision summary
    Australian prescription medicine decision summary